Generic HYDROCHLOROTHIAZIDE; PINDOLOL INN equivalents, drug patent and freedom to operate

Sponsor	Phase
VA Office of Research and Development
US Department of Veterans Affairs

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	VISKAZIDE	hydrochlorothiazide; pindolol	TABLET;ORAL	018872-002	Jul 22, 1987		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Novartis	VISKAZIDE	hydrochlorothiazide; pindolol	TABLET;ORAL	018872-001	Jul 22, 1987		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 9, 2026

Hydrochlorothiazide and pindolol are mature, low-cost antihypertensive drugs with limited branded revenue potential. Hydrochlorothiazide remains commercially relevant because of broad use in hypertension and edema, especially in combination products. Pindolol has a narrower and declining market because beta-blocker prescribing has shifted toward metoprolol, carvedilol, bisoprolol, nebivolol, and guideline-preferred therapies. The combined hydrochlorothiazide-pindolol opportunity is primarily generic and faces limited pricing power, low clinical differentiation, and little visible patent protection.

What are hydrochlorothiazide and pindolol used for?

Hydrochlorothiazide is a thiazide diuretic used for hypertension and edema. It is available as a standalone tablet and in numerous fixed-dose combinations with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and potassium-sparing agents.

Pindolol is a nonselective beta-adrenergic blocker with intrinsic sympathomimetic activity. The U.S. product was historically marketed under the Visken brand. Its use has declined as prescribers have favored other beta-blockers with broader evidence bases and stronger positions in heart failure, ischemic heart disease, arrhythmia, and post-myocardial-infarction treatment.

Attribute	Hydrochlorothiazide	Pindolol
Drug class	Thiazide diuretic	Nonselective beta-blocker
Primary use	Hypertension; edema	Hypertension and selected cardiovascular indications
U.S. commercial status	Widely available as generic	Generic; substantially narrower market
Typical dosage form	Oral tablets and combination tablets	Oral tablets
Patent maturity	Long expired	Long expired
Main commercial issue	High volume, minimal pricing power	Low volume and limited clinical differentiation
Main competitors	Chlorthalidone, indapamide, loop diuretics, combination products	Metoprolol, carvedilol, bisoprolol, atenolol, nebivolol
Biosimilar exposure	None	None

The combination of hydrochlorothiazide and pindolol historically targeted hypertension requiring dual therapy. Its market is now constrained by the widespread availability of newer fixed-dose combinations, including combinations built around renin-angiotensin system inhibitors.

How large is the hydrochlorothiazide market?

Hydrochlorothiazide has a large prescription footprint but low revenue per prescription. Its volume comes from chronic hypertension treatment and from fixed-dose combinations. The drug is commonly dispensed as a low-cost generic, and many manufacturers compete on supply, wholesaler contracts, and pharmacy purchasing terms.

Hydrochlorothiazide’s commercial value is concentrated in:

High prescription volume.
Combination products.
Government and managed-care formularies.
International generic markets.
Contract manufacturing and private-label supply.

The active ingredient itself has limited pricing power. Revenue increases generally depend on unit volume, supply disruptions, formulation changes, or entry into a combination product with stronger commercial demand.

Hydrochlorothiazide also faces clinical competition from chlorthalidone and indapamide. Some guidelines and comparative studies favor longer-acting thiazide-like diuretics for selected patients, although hydrochlorothiazide remains widely used because of familiarity, availability, and inclusion in many branded and generic combinations.

How large is the pindolol market?

Pindolol is a small mature generic market. Its commercial base is narrower than that of commonly used beta-blockers.

The principal factors limiting pindolol demand are:

Limited current guideline differentiation.
Strong generic competition from metoprolol and atenolol.
Greater use of carvedilol and bisoprolol in heart failure.
Preference for cardioselective beta-blockers in many patients.
Limited branded promotion.
Low reimbursement value and weak pricing leverage.

Pindolol’s intrinsic sympathomimetic activity can be clinically relevant in selected patients, particularly where clinicians seek to limit resting bradycardia or peripheral vasoconstriction. That property has not created a durable commercial niche comparable with the market positions of carvedilol, nebivolol, or metoprolol.

What is the FDA regulatory status of hydrochlorothiazide and pindolol?

Both active ingredients are established small-molecule drugs with long-standing FDA regulatory histories. Hydrochlorothiazide is marketed in multiple approved standalone and combination products. Pindolol has been marketed as a generic oral tablet following the expiration of the original branded product’s exclusivity.

The FDA’s Drugs@FDA and Orange Book databases are the relevant sources for determining the status of specific approved applications, therapeutic-equivalence codes, and listed patents. FDA records should be reviewed at the product and application level because the status of a combination product can differ from the status of the individual active ingredients.[1][2]

For commercial diligence, the relevant regulatory questions are:

Whether a particular hydrochlorothiazide or pindolol product has an active FDA approval.
Whether the product is listed as therapeutically equivalent to a reference product.
Whether the product is currently marketed.
Whether the combination has an active abbreviated new drug application.
Whether any patents or exclusivity statements remain listed for the specific product.

What patents protect hydrochlorothiazide and pindolol?

The core composition-of-matter patents for hydrochlorothiazide and pindolol expired many years ago. Neither active ingredient has a commercially meaningful period of remaining basic-molecule exclusivity in the United States.

Potentially relevant intellectual property can still arise from:

Specific fixed-dose combinations.
Modified-release delivery.
Tablet coatings or stability systems.
Manufacturing processes.
Crystalline or polymorphic forms.
Packaging and product-device combinations.
Method-of-use claims.

For conventional immediate-release hydrochlorothiazide and pindolol tablets, the principal commercial barrier is not patent protection. It is the economics of a low-margin generic market.

Are there active Orange Book patents for the combination?

No broad, commercially significant patent estate should be assumed for a conventional hydrochlorothiazide-pindolol immediate-release tablet. A product-specific Orange Book review is necessary because patents may be listed against an individual approved combination even when the underlying molecules are old.

A patent listing, if present, would not automatically establish strong market protection. Its value would depend on:

Claim scope.
Patent expiration date.
Whether the claim covers the marketed formulation.
Whether generic applicants must file Paragraph IV certifications.
Whether the listed patent is vulnerable to invalidity or noninfringement challenges.
Whether the reference product remains commercially important.

When does hydrochlorothiazide or pindolol lose exclusivity?

Both drugs lost meaningful regulatory exclusivity decades ago.

Hydrochlorothiazide is now a fully mature generic ingredient. Pindolol also has no material remaining new chemical entity exclusivity in the United States. Any current exclusivity analysis must focus on the specific product, not the molecule.

Exclusivity category	Hydrochlorothiazide	Pindolol
New chemical entity exclusivity	Expired	Expired
Core composition patent	Expired	Expired
Pediatric exclusivity	No material current protection expected	No material current protection expected
Orphan exclusivity	Not a core commercial feature	Not a core commercial feature
Formulation protection	Possible only for specific products	Possible only for specific products
Generic substitution	Broadly available for many products	Available but commercially narrower

What Paragraph IV challenges affect the products?

Paragraph IV litigation is unlikely to be a major current market driver for ordinary hydrochlorothiazide or pindolol tablets. Paragraph IV filings are most commercially consequential when a branded reference product has substantial sales and an active Orange Book patent. Neither condition generally applies to the core ingredients.

For a specific combination product, a generic applicant could challenge listed patents by certifying that the patents are invalid, unenforceable, or not infringed. The economic incentive would be limited unless the reference product retained substantial reimbursement or brand share.

The absence of significant current Paragraph IV activity is itself commercially relevant. It indicates that market entry is governed mainly by approval timing, manufacturing capacity, supply reliability, and contracting rather than by high-value patent litigation.

What formulation patents protect hydrochlorothiazide and pindolol?

Conventional immediate-release tablets generally have weak formulation differentiation. A potential formulation patent would need to claim a meaningful technical feature, such as:

A stable fixed-dose ratio.
A controlled-release profile.
Improved dissolution.
Reduced degradation.
Enhanced content uniformity.
A manufacturing process that produces a distinct solid form.
A delivery system with clinical or manufacturing advantages.

The commercial value of such patents would still depend on demand. A technically valid formulation patent has limited financial value if physicians and payers can substitute inexpensive separate tablets or alternative antihypertensive combinations.

For hydrochlorothiazide, combination-product patents have historically been more commercially relevant than standalone formulation patents. For pindolol, the small market limits the value of investment in complex delivery systems unless the formulation addresses a clear adherence or tolerability problem.

What is the generic launch risk for hydrochlorothiazide and pindolol?

Generic launch risk is high in the sense that barriers to entry are low, but the financial impact of new entry is modest because the market is already genericized.

Hydrochlorothiazide

Additional entry can reduce prices, but the large installed prescription base supports continued volume. Supply interruptions may temporarily improve pricing for manufacturers with available inventory. Long-term returns remain constrained by:

Multiple approved suppliers.
Low switching costs.
Pharmacy substitution.
Formulary pressure.
Limited differentiation.
Commodity-like active pharmaceutical ingredient sourcing.

Pindolol

Pindolol has lower generic-entry risk from a market-share perspective because the market is already small. New suppliers may not materially affect total category revenue. The larger risk is product discontinuation or supply instability if manufacturers conclude that the market does not justify continued production.

Which companies compete in the hydrochlorothiazide and pindolol markets?

Competition is fragmented and product-specific. Generic suppliers may include large multinational manufacturers, specialty generics companies, and regional contract manufacturers. The relevant competitive set changes by country and dosage strength.

For hydrochlorothiazide, competition includes manufacturers of:

Standalone hydrochlorothiazide tablets.
Hydrochlorothiazide plus lisinopril.
Hydrochlorothiazide plus losartan.
Hydrochlorothiazide plus valsartan.
Hydrochlorothiazide plus irbesartan.
Hydrochlorothiazide plus beta-blockers.
Hydrochlorothiazide plus potassium-sparing agents.

For pindolol, the key competitive products are not limited to other pindolol suppliers. The principal commercial substitutes are metoprolol tartrate, metoprolol succinate, atenolol, carvedilol, bisoprolol, nebivolol, and propranolol.

How does hydrochlorothiazide compare with pindolol commercially?

Metric	Hydrochlorothiazide	Pindolol
Market maturity	Mature generic	Mature generic
Prescription breadth	Broad	Narrow
Combination-product relevance	High	Limited
Clinical differentiation	Moderate within diuretic class	Limited versus modern beta-blockers
Pricing power	Very low	Very low
Supply-chain value	Meaningful because of volume	Limited because of low demand
Investment case	Volume, combinations, reliable supply	Niche supply and selected international markets
Patent-driven upside	Minimal	Minimal
Regulatory complexity	Moderate for combinations	Low for conventional tablets

Hydrochlorothiazide has the stronger commercial position because it is embedded in many high-volume hypertension regimens. Pindolol has a weaker trajectory because its clinical role is narrower and its substitute set is extensive.

What is the financial trajectory for these drugs?

Public financial reporting generally does not isolate revenue for generic hydrochlorothiazide or pindolol. Large pharmaceutical companies report portfolios or therapeutic areas rather than product-level sales for low-cost generic tablets. As a result, a precise global revenue figure cannot be reliably derived from public company filings.

The financial trajectory is nevertheless clear:

Hydrochlorothiazide: stable-to-declining price, durable volume, low unit economics, and occasional supply-driven margin volatility.
Pindolol: declining or flat demand, limited commercial investment, and potential manufacturer exits.
Fixed-dose hydrochlorothiazide-pindolol products: niche or declining revenue with limited prospects for premium pricing.
Branded relaunch opportunity: weak, absent a differentiated formulation, new indication, or compelling adherence benefit.

Revenue exposure is more meaningful for manufacturers with broad hypertension portfolios than for any single hydrochlorothiazide product. A supplier can generate stable aggregate sales through multiple strengths and combinations, but standalone product margins are generally vulnerable to tendering and wholesaler consolidation.

What licensing deals and business-development opportunities exist?

There is little basis for expecting major licensing transactions involving conventional hydrochlorothiazide, pindolol, or their immediate-release combination. The molecules are old, widely available, and not protected by meaningful core patents.

Potential transaction structures are more likely to involve:

Regional distribution rights.
Private-label supply.
Portfolio acquisitions.
Contract manufacturing.
Hospital or government tenders.
Combination-product registrations outside the United States.
Reformulations with adherence or modified-release claims.

A licensing transaction would require a commercial angle beyond the active ingredients, such as an approved product in an underserved market, a manufacturing advantage, or an established distribution network.

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers are operational rather than patent-based. They include:

Reliable supply of active pharmaceutical ingredient.
Validation of low-dose content uniformity.
Stability under heat and humidity.
Compliance with current good manufacturing practices.
FDA inspection readiness.
Batch-release testing.
Supply-chain continuity.
Registration requirements in each target jurisdiction.

Hydrochlorothiazide’s low selling price makes manufacturing efficiency critical. Pindolol’s smaller volume can create a different problem: minimum efficient batch sizes may be difficult to achieve, making continued production unattractive for some suppliers.

Geographic coverage varies significantly. FDA approval does not establish approval in the European Union, Canada, Japan, or emerging markets. Each jurisdiction applies its own registration, labeling, bioequivalence, serialization, and pharmacovigilance requirements.

Key Takeaways

Hydrochlorothiazide is a high-volume, low-margin generic with durable demand.
Pindolol is a smaller generic market with declining clinical prominence.
Both molecules have expired core patents and no meaningful remaining composition-of-matter exclusivity.
Conventional hydrochlorothiazide-pindolol tablets have limited patent and pricing protection.
Paragraph IV litigation is unlikely to drive the core market unless a specific combination product has active listed patents and meaningful sales.
Hydrochlorothiazide has stronger commercial prospects because of its extensive use in fixed-dose combinations.
Pindolol’s principal risk is demand erosion and manufacturer withdrawal, not patent-based generic entry.
Financial upside is more likely from supply reliability, regional distribution, or differentiated formulations than from the active ingredients themselves.
Public filings generally do not disclose product-level revenue for these mature generic drugs.
Biosimilar risk is not applicable because both products are small-molecule drugs, not biologics.

FAQs

Is hydrochlorothiazide still commercially attractive for generic manufacturers?

Yes, but primarily through volume, combination products, and reliable supply. Standalone margins are generally low.

Is pindolol still prescribed in the United States?

Yes, but at a much lower level than leading beta-blockers such as metoprolol, carvedilol, and atenolol.

Does hydrochlorothiazide have a biosimilar competitor?

No. Hydrochlorothiazide is a small-molecule drug and competes through generic approval rather than the biosimilar pathway.

Can a company obtain new patents on a hydrochlorothiazide-pindolol product?

A company may seek patents on a novel formulation, manufacturing process, delivery system, or method of use. Such patents would not restore exclusivity for the underlying molecules.

What would improve the commercial outlook for pindolol?

A commercially meaningful improvement would require a differentiated formulation, a validated clinical niche, a supply shortage in competing beta-blockers, or a strong regional distribution position.

References

U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (n.d.). Electronic Orange Book patent and exclusivity information. https://www.accessdata.fda.gov/scripts/ob/index.cfm
Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115. https://doi.org/10.1161/HYP.0000000000000065
U.S. National Library of Medicine. (n.d.). DailyMed: Current medication labeling. https://dailymed.nlm.nih.gov/dailymed/

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	6
Clinical Trials:	1
DailyMed Link:	hydrochlorothiazide; pindolol at DailyMed

Hydrochlorothiazide; pindolol - Generic Drug Details

What are the generic sources for hydrochlorothiazide; pindolol and what is the scope of freedom to operate?

Summary for hydrochlorothiazide; pindolol

Recent Clinical Trials for hydrochlorothiazide; pindolol

Anatomical Therapeutic Chemical (ATC) Classes for hydrochlorothiazide; pindolol

US Patents and Regulatory Information for hydrochlorothiazide; pindolol

Hydrochlorothiazide and Pindolol Market Dynamics, Patent Status, and Financial Trajectory